Article information
Abstract
Background
Extended spectrum β-lactamase (ESBL)-producing bacteria have become recognized as a problem in South America. The aim of this study was to evaluate risk factors and mortality rate in bacteremia caused by ESBL-producing Klebsiella pneumoniae in a Brazilian hospital.
MethodsA three-year retrospective cohort study with 104 cases of K. pneumoniae bacteremia (61 ESBL and 43 non-ESBL). Several clinical and laboratory variables were evaluated. The outcome of interest was 30-day mortality. The adequate treatment was evaluated according to antibiotic susceptibility.
ResultsMultivariable analysis showed that central venous catheter and mechanical ventilation were independent risk factors for ESBL. The duration of hospitalization before the bacteremia was not a risk factor. Mortality was similar in ESBL and non-ESBL and inadequate therapy was not shown to be a risk factor.
ConclusionESBL-producing Klebsiella bacteremia can occur early, suggesting that a carbapenem should be included in the initial empirical therapy for bacteremia in patients under mechanical ventilation and/or central venous catheter in our institution.
Keywords:
Klebsiella pneumoniae
beta-lactamases
bacteremia
carbapenems
Full text is only aviable in PDF
References
[1.]
E. Girao, A.S. Levin, M. Basso, et al.
Trends and outcome of 1121 nosocomial bloodstream infections in intensive care units in a Brazilian hospital, 1999–2003.
Int J Infect Dis, 12 (2008), pp. e145-e146
[2.]
H.S. Sader, R.N. Jones, S. Andrade-Baiocchi, et al.
Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers.
Diagn Microbiol Infect Dis, 44 (2002), pp. 273-280
[3.]
M. York.
Aerobic Bacteriology.
Clinical Microbiology Procedures Handbook: 3. 17. 1-3. 17. 48.,
[4.]
Clinical and Laboratory Standard Institute.
Performance standards for antimicrobial disk susceptibility testing; Fifteenth Informational Supplement.
Clinical and Laboratory Standard Institute, (2005),
[5.]
A.R. Marra, C.A. Pereira, A. Castelo, et al.
Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection.
Int J Infect Dis, 10 (2006), pp. 56-60
[6.]
F. Rossi, F. Baquero, P.R. Hsueh, et al.
In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).
J Antimicrob Chemother, 58 (2006), pp. 205-210
[7.]
C. Kiffer, A. Hsiung, C. Oplustil, et al.
Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003.
Braz J Infect Dis, 9 (2005), pp. 216-224
[8.]
D.L. Paterson, W.C. Ko, G.A. Von, et al.
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended- spectrum beta-lactamase production in nosocomial Infections.
Ann Intern Med, 140 (2004), pp. 26-32
[9.]
K. Urbanek, M. Kolar, Y. Loveckova, et al.
Influence of thirdgeneration cephalosporin utilization on the occurrence of ESBL- positive Klebsiella pneumoniae strains.
J Clin Pharm Ther, 32 (2007), pp. 403-408
[10.]
E.P. Hyle, W.B. Bilker, L.B. Gasink, et al.
Impact of different methods for describing the extent of prior antibiotic exposure on the association between antibiotic use and antibiotic-resistant infection.
Infect Control Hosp Epidemiol, 28 (2007), pp. 647-654
[11.]
E. Calbo, V. Romani, M. Xercavins, et al.
Risk factors for community- onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
J Antimicrob Chemother, 57 (2006), pp. 780-783
[12.]
D.L. Paterson, W.C. Ko, G.A. Von, et al.
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections.
Ann Intern Med, 140 (2004), pp. 26-32
[13.]
A.R. Marra, S.B. Wey, A. Castelo, et al.
Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence.
BMC Infect Dis, 6 (2006), pp. 24
[14.]
E.M. Trecarichi, M. Tumbarello, T. Spanu, et al.
Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.
J Infect, 58 (2009), pp. 299-307
[15.]
J.I. Memon, R.S. Rehmani, M.U. Ahmed, et al.
Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia Risk factors and outcome in the eastern region of Saudi Arabia.
Saudi Med J, 30 (2009), pp. 803-808
[16.]
G. Menashe, A. Borer, P. Yagupsky, et al.
Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia.
Scand J Infect Dis, 33 (2001), pp. 188-193
[17.]
B. Du, Y. Long, H. Liu, et al.
Extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
Intensive Care Med, 28 (2002), pp. 1718-1723
[18.]
D.L. Paterson, W.C. Ko, G.A. Von, et al.
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.
Clin Infect Dis, 39 (2004), pp. 31-37
Copyright © 2011. Elsevier Editora Ltda.. All rights reserved
